Interim Results

Smiths Group PLC 13 March 2002 Smiths Group: Interim Results for the 6 months ended 31 January 2002 Highlights: - Operating profit of £201m from continuing activities, 11% down - Strong cash-flow maintained, profit-to-cash conversion at 80% - Growing defence activity is limiting the impact of civil aerospace downturn - Rapid restructuring has reduced the cost base in all divisions - Sale of marine seals will bring debt to circa £900m - Smiths selected by Boeing for 767 tanker refuelling system - Dividend maintained at 8.75p - More confidence in outlook for second half Commenting on the results, Keith Butler-Wheelhouse, Chief Executive said: 'This was an exceptionally tough six months for many companies. Against challenging circumstances, our 13% first-half margins and 80% profit-to-cash conversion show the resilience of Smiths Group. Meanwhile, we have been focusing on disposals and restructuring so that we can return to growth as the economic cycle starts to recover. Our defence business is already growing strongly and recent acquisitions will help Medical make a bigger contribution. We are now more confident about the outlook for the second half of the year.' Further information: Russell Plumley +44 (0) 20 8457 8203 russell.plumley@smiths-group.com Reported on a fully consolidated basis, including discontinued activities and after exceptionals and amortisation, Smiths Group recorded pre-tax profit of £123 million (2001: £97m) and earnings per share of 14.0p (7.7p) in the first half of the current year, with the prior period bearing one-off merger-related costs. The remainder of this statement focuses on the continuing activities. Performance of the continuing activities £m 2002 2001 Turnover 1,491 1,530 Operating profit* 201 226 Interest (27) (26) Pre-tax profit* 174 200 Earnings per share* 22.4p 25.4p Restructuring charges 8 68 Interim dividend 8.75p 8.75p *before exceptionals and amortisation For the six months ended 31 January 2002, Smiths Group generated operating profit of £201 million (down 11%), pre-tax profit of £174 million and earnings per share of 22.4p, before exceptional charges and amortisation. The Board has declared an interim dividend maintained at last year's level of 8.75p. On slightly reduced sales of £1.49 billion, the company achieved a profit margin of 13%. The company maintained its strong record of cash generation, converting 80% of operating profit into operating cash after capital expenditure. On completion of the sale of the marine seals business, net debt will fall to circa £900 million. Aerospace, largest of the company's divisions, contributed 40% of operating profit. Continued growth and high margins in Medical raised its proportion of profit to 23%, one point ahead of Sealing Solutions. Industrial, most affected by market slowdown, contributed 15% of the total this time. More than half of the company's sales and profits originate from the United States. Business in the US held up well, particularly in the defence and medical sectors. Demand there for consumer and industrial products reduced, and the slowdown in US domestic air travel began to have some effect on Smiths Aerospace. Business in the UK and continental Europe was generally flat, with the depressed state of the German economy having an impact on Sealing Solutions. Currency variations had little effect on the results, although the decline of the Yen reduced the reported contribution to Medical from the important Japanese market. Three acquisitions at a combined cost of £51 million were added to the Medical and Interconnect activities. The sale of the John Crane-Lips marine seals business to Wartsila was announced in December. Completion is expected shortly, following receipt of the remaining two regulatory approvals, and consequently its sales and profits have been treated as discontinued. Smiths will then have generated £259m from disposals since the start of the financial year. The 2001 sales and profits of these non-core activities were £289m and £25m respectively. The first half disposals gave rise to an exceptional loss of £23 million against book value. The company incurred exceptional costs of £8 million on restructuring its civil aerospace business and on the forthcoming transfer of production from a US Medical facility to Mexico. Further exceptionals in the range of £35-40 million are expected in the second half to complete the restructuring of civil aerospace, including the closure of facilities in the UK and US. The restructuring continues to affect employment. In the first half, 1,600 jobs were lost across all divisions, and a further 450 direct labour jobs were transferred to Mexico and the Czech Republic. In the second half and the early part of next (financial) year, 1,450 jobs will be eliminated and 450 transferred. In total, 1,200 of the job cuts are in the UK. In last year's accounts, Smiths Group published its pension funding status calculated under FRS 17. On this basis, pension assets exceeded liabilities by £319 million - a funding ratio of 114%. Pension costs charged to operating profit increased by £5 million in the period, reflecting lower investment returns. Aerospace £m 2002 2001 Turnover 639 596 Operating profit 80 84 Margin 13% 14% On increased sales, Smiths Aerospace recorded a 5% drop in profits, mainly due to a changing mix of programmes. Sales of defence equipment, now half of the total, climbed by 20%, and sales of the still relatively small detection and protection business increased by 50%. These gains outweighed the start of a slowdown in the civil aerospace sector. The company strengthened its position as a first-tier aerospace supplier by winning defence contracts which will generate significant revenue through the present decade. Among these, Lockheed Martin selected Smiths as a partner on the F-35 Joint Strike Fighter (JSF). So far, Smiths has secured agreements to supply systems valued at $1 million per aircraft on the JSF programme, and funded development is already underway. Although it is clear that the civil aerospace sector will go through a downturn over the next two years, the effect in the half year was less serious than originally expected. Operational difficulties for airlines in the wake of 9/11 affected aftermarket sales, but the reduction in aircraft production is only now starting to affect sales of original equipment. Civil aerospace accounts for 35% of divisional sales, and major restructuring is underway to align capacity with demand. Airline load factors have recently started to improve and this is the first positive indicator for the industry since September. Within Aerospace, there is a rapidly growing business in detection and protection systems for military and civilian use. These systems provide warning of chemical and biological threats, and detect traces of explosives and narcotics on individuals or in baggage. The requirement for enhanced airport security has generated unprecedented demand, and new products are being added to the range to address these opportunities. Boeing announced today the selection of Smiths Aerospace to provide an integrated refuelling system for the Global Tanker Transport Aircraft (GTTA) programme, based on the Boeing 767 commercial aircraft. Joining this Boeing team provides Smiths with the potential to supply systems and in-service support valued at more than $1 billion over the next 30 years. This contract exploits the synergy benefits of bringing a range of capabilities from across Smiths Aerospace into an integrated system. Adding to its expertise in this area, the company has reached agreement to acquire Able Corporation of Los Angeles for $17.5 million plus a deferred amount of up to $10 million over 5 years. Able will supply the refuelling hose unit within the Smiths system for the GTTA programme. Medical £m 2002 2001 Turnover 224 217 Operating profit 46 43 Margin 20% 20% Smiths Medical achieved a 7% increase in profit on a modest increase in sales, leaving margins unchanged at 20%. The comparative period last year was exceptionally strong, due to a one-off surge in spending by the UK's National Health Service. Medical has reorganised into product-specific global business units. The largest, airway management, makes the Portex branded single-use devices which put the company among the world leaders in this market. Other business units focus on pain management, ambulatory and hospital infusion, patient temperature management, critical care monitoring and assisted reproduction. The division's production is being consolidated into fewer locations, and labour-intensive assembly is being moved to Mexico, where employment will reach nearly 1,000 next year. The efficiency gains realised are funding an increased rate of new product development. Among recently introduced products are additional applications for the Needle Pro safety device which helps prevent needlestick injuries. Sales of these devices, which are a legal requirement in US hospitals, grew by 50% in this period. Medical now has a targeted approach to generating new business with the major hospital buying groups in the US, and this has resulted in more firmly established positions with groups including Novation, Premier and Broadlane. Two recent acquisitions complement existing activities. In November, the company paid £25 million for Bivona Inc, based in Indiana. Bivona specialises in airway management products made of silicon, which are used when the tubes are going to be left in place for longer than usual. In January, the company announced it would pay £18 million (partly deferred) to acquire a product line of anaesthesia procedure kits from Abbott Laboratories. Procedure kits are increasingly preferred by consultants because they save the hospital from having to provide a set of individual devices for each operation. Smiths Medical's business in Japan is a significant contributor to the performance of the division. Japan Medico is bringing to market a progressively wider range of Smiths products. However, the weaker Yen impacted consolidated sales by £4m in the period. Sealing Solutions £m 2002 2001 Turnover 410 462 Operating profit 45 51 Margin 11% 11% Following the disposal of several non-core activities, including marine seals, the Sealing Solutions division now comprises John Crane and the polymer seals business. Sales and profits declined by 11% on a like-for-like basis, leaving margins unchanged at 11%. John Crane, generating just over half of continuing divisional sales, is the world leader in metal and ceramic rotating seals used in process plant, including the oil & gas, pulp & paper and chemical industries. These are high added-value, engineered seals which generate significant aftermarket revenues. While John Crane's sales were flat in this period, the benefits of restructuring are now coming through in terms of improved margins. Labour-intensive production has been transferred to lower cost countries, and the product range has been rationalised to focus on the most profitable applications. John Crane is now in good shape to take advantage of an improving outlook in its major markets. The decline in divisional sales and profits was largely attributable to poor market conditions facing the polymer seals business. It supplies high-grade rubber and plastic seals for the industrial, automotive and aerospace sectors. Over half of its sales are into the European industrial equipment market, and these were seriously impacted by the decline in capital goods production, particularly in Germany, during this period. A quarter of sales are for automotive applications, and these too have been at lower levels. As with John Crane, restructuring is underway. Industrial £m 2002 2001 Turnover 218 255 Operating profit 30 49 Margin 14% 19% Sales by the Industrial division were 15% down and profits declined by 39%, against the prior period, which benefited from the telecoms peak. Restructuring has taken place across the division reflecting the present lower levels of activity, and the costs of this have been charged against profits. Overall personnel numbers are 10% lower than a year ago. The Interconnect businesses serving the wireless telecoms sector were seriously affected by the downturn in this market. Smiths products are mainly used for protection and connection of electronics in the base stations and transmission towers of mobile networks. Expansion of these networks has slowed while the service providers seek to regain profitability, and customer destocking continued through this period. Twelve months ago, activity was at an unprecedented high. Even at today's levels, the Smiths telecom-related businesses are generating mid-teens margins and a return on investment well above the cost of capital. Interconnect business in other sectors was less severely affected. Sales of connectors for defence use, including Eurofighter and a number of US programmes, continued to grow. This was offset by a decline in general industrial applications. Sales by the air movement businesses including Vent-Axia were flat. The flexible ducting and hosing businesses performed well, although their products for household goods were affected by reduced consumer spending in the US. In December the company paid £8 million to acquire Summitek, a US company specialising in test and measurement equipment used in the wireless communications industry. Prospects Smiths Group is now more confident about the outlook for the second half of the year. The first half shortfall of 11% in operating profit was less than indicated in November, and the second half decline is expected to be similar or less. Recent disposals have helped increase the focus on the core activities, with the defence and healthcare sectors now providing the greatest opportunities for growth. The company remains on track to achieve the merger-related savings outlined a year ago, and further restructuring is in hand to address the civil aerospace downturn. With a robust balance sheet and strong cash generation, Smiths is in good shape to take advantage of any improvement in its markets. Dividend The Board has declared an interim dividend of 8.75p, unchanged from a year ago, and will consider whether or not to increase the final dividend in the light of circumstances prevailing in six months' time. The interim dividend will be paid on 19 April 2002 to holders of all ordinary shares whose names are registered at the close of business on 22 March. The ex-dividend date will be 20 March. Copies of the interim report will be sent to shareholders shortly, and will be available at the company's registered office, 765 Finchley Road, London NW11 8DS. Tables attached - Profit & loss account - Summarised balance sheet - Cash-flow statement - Notes to the accounts The financial statements attached have been prepared in accordance with the accounting policies set out in the company's accounts for the year ended 31 July 2001. The company has adopted FRS 19 (Deferred Taxation) in these interim accounts. Figures relating to last year are abridged. Full accounts for Smiths Group plc to 31 July 2001, on which the auditors made an unqualified report, have been delivered to the Registrar of Companies. Profit and loss account 6 months ended 31 January 2002 Ordinary Discontinued Goodwill Exceptional Total Activities Businesses Amortisation Items Note £m £m £m £m £m Continuing operations 1,486.8 1,486.8 Acquisitions 4.3 4.3 Discontinued businesses 96.6 96.6 Turnover 1 1,491.1 96.6 1,587.7 Continuing operations 199.7 (18.4) (7.6) 173.7 Acquisitions 1.1 (0.4) 0.7 Discontinued businesses 6.3 6.3 Operating profit 200.8 6.3 (18.8) (7.6) 180.7 Exceptional items - 2 profit / (loss) on disposal (23.4) (23.4) of businesses Profit before interest and tax 200.8 6.3 (18.8) (31.0) 157.3 Net interest payable (27.3) (6.9) (34.2) Profit before taxation 173.5 (0.6) (18.8) (31.0) 123.1 Taxation (48.6) 0.2 1.8 2.1 (44.5) Profit / (loss) after taxation 124.9 (0.4) (17.0) (28.9) 78.6 Minority interests (0.7) (0.7) Profit / (loss) for the period 124.2 (0.4) (17.0) (28.9) 77.9 Dividends 3 (48.6) (48.6) Retained profit / (loss) 75.6 (0.4) (17.0) (28.9) 29.3 Earnings per share 4 Basic 22.4p (0.1p) (3.1p) (5.2p) 14.0p Fully-diluted 22.3p (0.1p) (3.1p) (5.2p) 13.9p Profit and loss account 6 months ended 31 January 2001 Ordinary Discontinued Goodwill Exceptional Total Activities Businesses Amortisation Items Note £m £m £m £m £m Continuing operations 1,530.1 1,530.1 Acquisitions Discontinued businesses 948.6 948.6 Turnover 1 1,530.1 948.6 2,478.7 Continuing operations 225.9 (23.9) (67.6) 134.4 Acquisitions Discontinued businesses 90.4 (17.7) 72.7 Operating profit 225.9 90.4 (23.9) (85.3) 207.1 Exceptional items - 2 merger costs (53.8) (53.8) Profit before interest and tax 225.9 90.4 (23.9) (139.1) 153.3 Net interest payable (26.3) (29.8) (56.1) Profit before taxation 199.6 60.6 (23.9) (139.1) 97.2 Taxation (59.9) (18.2) 2.6 21.0 (54.5) Profit / (loss) after taxation 139.7 42.4 (21.3) (118.1) 42.7 Minority interests (0.6) (0.6) Profit / (loss) for the period 139.1 42.4 (21.3) (118.1) 42.1 Dividends 3 (109.1) (109.1) Retained profit / (loss) 30.0 42.4 (21.3) (118.1) (67.0) Earnings per share 4 Basic 25.4p 7.7p (3.9p) (21.5p) 7.7p Fully-diluted 25.3p 7.7p (3.9p) (21.5p) 7.6p Profit and loss account Year ended 31 July 2001 Ordinary Discontinued Goodwill Exceptional Total Activities Businesses Amortisation Items Note £m £m £m £m £m Continuing operations 3,177.1 3,177.1 Acquisitions Discontinued businesses 1,781.1 1,781.1 Turnover 1 3,177.1 1,781.1 4,958.2 Continuing operations 499.8 (34.6) (115.8) 349.4 Acquisitions Discontinued businesses 151.5 (14.1) (17.7) 119.7 Operating profit 499.8 151.5 (48.7) (133.5) 469.1 Exceptional items - 2 merger costs (54.2) (54.2) profit / (loss) on (286.0) (286.0) disposal of businesses write-down of goodwill on (125.0) (125.0) future anticipated disposals Profit before interest and tax 499.8 151.5 (48.7) (598.7) 3.9 Net interest payable (59.1) (57.1) (116.2) Profit before taxation 440.7 94.4 (48.7) (598.7) (112.3) Taxation (127.9) (28.3) 3.6 60.5 (92.1) Profit / (loss) after taxation 312.8 66.1 (45.1) (538.2) (204.4) Minority interests (1.1) (0.5) (1.6) Profit / (loss) for the period 311.7 65.6 (45.1) (538.2) (206.0) Dividends (199.5) (199.5) Retained profit / (loss) 112.2 65.6 (45.1) (538.2) (405.5) Earnings per share 4 Basic 56.4p 11.9p (8.2p) (97.4p) (37.3p) Fully-diluted 56.2p 11.8p (8.1p) (97.0p) (37.1p) Summarised balance sheet 31 January 2002 31 January 2001 31 July 2001 Note £m £m £m Fixed assets Intangible assets 708.4 923.0 678.3 Tangible assets 607.8 1,017.5 620.1 Investments and advances: Automotive 325.0 18.9 325.0 Other 13.2 9.2 12.1 1,654.4 1,968.6 1,635.5 Current assets Stocks 576.9 663.4 567.6 Debtors 837.4 1,255.6 918.6 Cash at bank 201.8 120.6 117.2 1,616.1 2,039.6 1,603.4 Creditors: amounts falling due within one year (1,058.4) (1,435.1) (1,181.4) Net current assets 557.7 604.5 422.0 Total assets less current liabilities 2,212.1 2,573.1 2,057.5 Creditors: amounts falling due after one year (1,089.6) (1,586.2) (970.2) Provisions for liabilities & charges (228.9) (256.1) (234.9) Net assets 893.6 730.8 852.4 Capital and reserves Share capital and share premium account 287.6 277.3 285.0 Reserves 592.5 439.5 554.7 Shareholders' equity 7 880.1 716.8 839.7 Minority equity interests 13.5 14.0 12.7 Capital employed 893.6 730.8 852.4 Comparative figures for provisions for liabilities and charges and reserves have been restated on the adoption of FRS 19 to include an additional deferred taxation provision of £26m relating to past tax benefits derived from goodwill acquired before 1 August 1998 and written off against reserves under accounting policies in force at that time. Cash-flow statement 6 months 6 months Year ended ended ended 31 January 31 January 31 July 2002 2001 2001 Note £m £m £m Operating profit (before restructuring and merger costs) 188.3 292.4 602.6 Goodwill amortisation 18.8 23.9 48.7 Depreciation 46.6 69.8 139.3 (Increase) / decrease in stocks (31.0) (28.3) (34.4) (Increase) / decrease in debtors 52.4 (22.8) (71.7) Increase / (decrease) in creditors (59.1) (5.3) 19.5 Other non-cash items (2.8) (3.0) Operating cash-flow before restructuring costs 216.0 326.9 701.0 Restructuring costs (26.0) (30.9) (74.2) Operating cash-flow after restructuring costs 190.0 296.0 626.8 Merger costs (49.6) (54.2) Returns on investments and servicing of finance (28.6) (50.8) (117.9) Tax paid (19.6) (60.7) (115.6) Capital expenditure and financial investment (50.4) (105.7) (188.0) Acquisitions and disposals 5 (3.7) (95.4) 400.9 Deferred consideration re prior-year acquisitions (26.3) (32.3) Equity dividends paid (90.4) (122.8) (171.3) Management of liquid resources (38.4) 195.2 193.6 Financing 93.5 (123.1) (448.2) Increase / (decrease) in cash 52.4 (143.2) 93.8 Increase/ (decrease) in short-term deposits 38.4 (195.2) (193.6) (Increase) / decrease in other borrowings (92.2) 127.9 452.8 Loan note issues (net of repayments) 0.7 2.2 3.5 Term debt of acquisitions assumed (0.5) Term deposits acquired with acquisitions 19.0 Debt de-consolidated on disposals 19.1 Exchange variations (6.9) (22.8) (48.7) (Increase) / decrease in net debt (7.6) (231.6) 345.9 Net debt at beginning of period (1,119.8) (1,465.7) (1,465.7) Net debt at end of period 6 (1,127.4) (1,697.3) (1,119.8) Notes to the accounts 6 months ended 6 months ended Year ended 31 January 2002 31 January 2001 31 July 2001 Turnover Profit Turnover Profit Turnover Profit 1. Analyses of turnover and profit £m £m £m £m £m £m Market Aerospace 638.7 79.8 596.4 83.5 1,303.6 208.5 Medical 224.1 46.0 217.2 42.8 452.5 93.3 Sealing Solutions 409.9 45.0 461.5 50.6 913.2 105.4 Industrial 218.4 30.0 255.0 49.0 507.8 92.6 1,491.1 200.8 1,530.1 225.9 3,177.1 499.8 Discontinued businesses 96.6 6.3 948.6 90.4 1,781.1 151.5 1,587.7 207.1 2,478.7 316.3 4,958.2 651.3 Goodwill amortisation (18.8) (23.9) (48.7) Exceptional items (31.0) (139.1) (598.7) Profit before interest and tax 157.3 153.3 3.9 Net interest (34.2) (56.1) (116.2) Profit before taxation 123.1 97.2 (112.3) Geographical origin - continuing activities United Kingdom 486.1 51.9 494.5 65.5 1,042.1 119.9 USA 767.0 102.3 752.3 113.6 1,622.7 271.2 US dollars $1,112.2m $148.3m $1,098.4m $165.9m $2,352.9m $393.2m Europe 238.3 27.8 230.0 31.6 508.2 71.6 Other overseas 124.5 18.8 111.9 15.2 238.9 37.1 Inter-company (124.8) (58.6) (234.8) 1,491.1 200.8 1,530.1 225.9 3,177.1 499.8 John Crane Lips has been treated as discontinued. The agreement to sell the business is conditional upon final regulatory approvals, all but two of which have already been obtained, and the remainder are expected shortly. 2. Exceptional items 2002 2001 2001 £m £m £m Restructuring and closure costs (7.6) (85.3) (133.5) Merger costs (53.8) (54.2) (7.6) (139.1) (187.7) Loss on disposal of businesses (23.4) (286.0) Goodwill on anticipated disposals (125.0) (31.0) (139.1) (598.7) The book value of assets sold amounted to £62.6m and net sale proceeds £39.2m (2001 £1,205.9m including goodwill £626.6m; net sale proceeds £919.9m). 3. Dividends An interim dividend of 8.75p per share ( 2001: 8.75p) has been declared and will be paid on 19 April 2002 to holders of all ordinary shares whose names are registered at close of business on 22 March 2002. 4. Earnings per share Separate figures are given for earnings per share related to the average number of shares in issue for each period - 6 months ended 31 Year ended 31 July January 2002 2001 2001 Basic 555,903,263 548,963,057 552,770,686 Effect of dilutive share options 1,021,646 1,343,271 2,113,803 Fully - diluted 556,924,909 550,306,328 554,884,489 5. Acquisitions and disposals During the period the Company acquired the issued share capital of Bivona Inc., and the business assets of a product line from Abbott Laboratories for Medical, and the issued share capital of Summitek Instruments, Inc. for Industrial. Details of the consideration paid, amounts treated as goodwill and the net assets acquired are set out below. These values are provisional, and following completion of the ongoing review, will be finalised in subsequent financial statements. Date of Consideration Goodwill Net Assets Acquisition £m £m £m Bivona 31.10.01 25.6 20.4 5.2 Abbott anaesthesia kit business 20.12.01 18.0 17.0 1.0 Summitek 2.12.01 7.6 6.1 1.5 51.2 43.5 7.7 Consideration deferred 8.3 Cash outflow in period 42.9 Net proceeds of disposals (note 2) (39.2) Net cash outflow 3.7 In addition to the £18m paid for the Abbott business and assets, the company has undertaken to acquire stocks of raw materials and finished goods at an estimated cost of £3m. In accordance with the provisions of FRS 10, the company amortises goodwill arising on acquisitions after 1 August 1998 on a straight-line basis over a period of up to 20 years. The charge for the period to 31 January 2002 was £18.8m. 6. Borrowings and net debt 31 January y 31 January 2001 31 July 2001 20022 Fixed Floating £m £m £m £m £m Maturity: On demand/under one year 49.7 264.4 314.1 362.4 342.6 One to two years 19.8 0.1 19.9 204.2 90.6 Two to five years 143.0 554.9 697.9 946.7 506.8 Greater than five years: Bank loans 1.3 1.3 8.8 1.1 TI Eurosterling bond 2010 148.4 148.4 148.3 148.3 Smiths Eurosterling bonds 2016 147.6 147.6 147.5 147.6 361.4 967.8 1,329.2 1,817.9 1,237.0 Cash and deposits (201.8) (120.6) (117.2) Net debt 1,127.4 1,697.3 1,119.8 2002 2001 7. Movements in shareholders' equity Note £m £m £m £m Profit for the period 77.9 42.1 Dividends (48.6) (109.1) 29.3 (67.0) Exchange variations 9.1 (2.9) Share issues 2.0 25.3 Net increase/ (reduction) in shareholders' equity 40.4 (44.6) Shareholders' equity : at 1 August 2001 865.7 787.4 Prior period adjustment - FRS 19 8 (26.0) 839.7 (26.0) 761.4 at 31 January 2002 880.1 716.8 8. Accounting policies The company has adopted FRS 19 - Deferred Taxation. As a result, an adjustment of £26m has been made to opening reserves to reflect the deferral of tax relating to goodwill acquired before 1 August 1998, and written off to reserves under accounting policies in force at that time. The effect on the reported profits of the prior period is not material. -ends- page 17 of 17 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings